TLSA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Tiziana Life Sciences Ltd (TLSA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the MACD and RSI indicators suggest some stability, the bearish moving averages and pre-market price decline indicate a lack of upward momentum. Additionally, there are no recent positive news catalysts, significant financial data, or strong proprietary trading signals to support a buy decision. Given the investor's background and the lack of compelling data, holding off on this stock for now is the most prudent choice.
The MACD histogram is positive at 0.0085 and expanding, indicating a potential upward trend. However, the RSI at 63.486 is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are Pivot: 1.351, R1: 1.454, S1: 1.248, R2: 1.518, S2: 1.184. The pre-market price of $1.4 is below R1 and close to the pivot, showing limited upward momentum.
The MACD is positively expanding, which could indicate potential upward momentum. Analysts have an Outperform rating with a $12.50 price target, suggesting long-term growth potential.
Bearish moving averages and a pre-market price decline of -4.11% indicate weak short-term momentum. There are no recent news catalysts, significant insider or hedge fund trading activity, or congress trading data to support a buy decision.
No financial data available for analysis.
Northland has named TriSalus Life Sciences (TLSA) as a Top Pick for 2026 with an Outperform rating and a $12.50 price target. The analyst expects the TriNav franchise to gain market share in embolization procedures.
